Mechanism of action of and resistance to quinolones

被引:63
作者
Bearden, DT
Danziger, LH
机构
[1] Univ Illinois, Coll Pharm, Dept Pharm Practice MC886, Sect Infect Dis Pharmacotherapy, Chicago, IL 60612 USA
[2] Oregon State Univ, Coll Pharm, Portland, OR USA
来源
PHARMACOTHERAPY | 2001年 / 21卷 / 10期
关键词
D O I
10.1592/phco.21.16.224S.33997
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A topoisomerase was identified as the bacterial target site for quinolone action in the late 1970s. Since that time, further study identified two bacterial topoisomerases, DNA gyrase and topoisomerase IV, as sites of antibacterial activity DNA gyrase appears to be the primary quinolone target for gramnegative bacteria. Topoisomerase IV appears to be the preferential target in gram-positive organisms, but this varies with the drug. Three mechanisms of resistance against quinolones are mutations of topoisomerases, decreased membrane permeability, and active drug efflux. Although these mechanisms occur singly, several resistance factors are often required to produce clinically applicable increases in minimum inhibitory concentrations. Appropriate drug selection and dosage and prudent human and veterinary interventions are important factors in controlling the emergence of resistance.
引用
收藏
页码:224S / 232S
页数:9
相关论文
共 88 条
[11]   Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae [J].
Brenwald, NP ;
Gill, MJ ;
Wise, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (08) :2032-2035
[12]   Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae [J].
Broskey, J ;
Coleman, K ;
Gwynn, MN ;
McCloskey, L ;
Traini, C ;
Voelker, L ;
Warren, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 :95-99
[13]   ROLE OF MUTATIONS IN DNA GYRASE GENES IN CIPROFLOXACIN RESISTANCE OF PSEUDOMONAS-AERUGINOSA SUSCEPTIBLE OR RESISTANT TO IMIPENEM [J].
CAMBAU, E ;
PERANI, E ;
DIB, C ;
PETINON, C ;
TRIAS, J ;
JARLIER, V .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (10) :2248-2252
[14]  
CHAUVEL M, 1999, 39 INT C ANT AG CHEM
[15]   Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada [J].
Chen, DK ;
McGeer, A ;
de Azavedo, JC ;
Low, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (04) :233-239
[16]  
CONRAD S, 1996, J ANTIMICROB CHEMOTH, V38, P433
[17]   Association of mutations in grlA and gyrA topoisomerase genes with resistance to ciprofloxacin in epidemic and sporadic isolates of methicillin-resistant Staphylococcus aureus [J].
Deplano, A ;
Zekhnini, A ;
Allali, N ;
Couturier, M ;
Struelens, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (09) :2023-2025
[18]   Levofloxacin selects fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus less frequently than ciprofloxacin [J].
Evans, ME ;
Titlow, WB .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 41 (02) :285-288
[19]   Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals [J].
Everett, MJ ;
Jin, YF ;
Ricci, V ;
Piddock, LJV .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) :2380-2386
[20]   ANALYSIS OF GYRA AND GRLA MUTATIONS IN STEPWISE-SELECTED CIPROFLOXACIN-RESISTANT MUTANTS OF STAPHYLOCOCCUS-AUREUS [J].
FERRERO, L ;
CAMERON, B ;
CROUZET, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (07) :1554-1558